What's Happening?
A new conceptual clinical service model, the Mainstreaming OncoGenomics Model (MOGO), has been developed to integrate genomic testing into oncology settings, specifically targeting Lynch syndrome and other hereditary cancers. This model, based on the Genomic Medicine
Integrative Research framework, aims to streamline genetic testing processes and improve access to genetic counseling. The model identifies key organizational factors and interventions necessary for successful implementation, such as embedding genetic counselors and utilizing electronic medical records for genetic test ordering and results tracking. The model's development involved a systematic review and qualitative and quantitative studies, highlighting the need for improved genetic test access and streamlined care processes.
Why It's Important?
The implementation of the MOGO model could significantly impact the healthcare system by improving the identification and management of hereditary cancers like Lynch syndrome. By integrating genetic testing into routine oncology care, the model aims to enhance early detection and risk-reducing measures, potentially reducing cancer-related morbidity and mortality. This approach could lead to more personalized and preventive healthcare, benefiting patients with hereditary cancer risks. Additionally, the model addresses barriers such as funding and infrastructure, which are crucial for the widespread adoption of genetic testing in oncology.
What's Next?
Future research and evaluation of the MOGO model are necessary to assess its effectiveness in real-world settings. The model's implementation will require collaboration among healthcare professionals, policymakers, and genetic counselors to ensure its success. As the model is tested and refined, it could serve as a blueprint for integrating genomic testing into other areas of healthcare, potentially leading to broader applications in personalized medicine.
